-

Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund

VALLETTA, Malta--(BUSINESS WIRE)--kENUP Foundation has presented €100,000 donation into Malta’s COVID-19 R&D Fund. The Fund is managed jointly by the Malta Council for Science and Technology (MCST) and Malta Enterprise with the support of the Ministry for Finance and Financial Services, and the Ministry for the Economy, Investment & Small Businesses. The Malta fund will see €5.3M funnelled into developing innovative and improved scientific and technological approaches to the challenges raised by COVID-19 and future pandemics.

kENUP, a Malta-based not-for-profit global partnership in innovation, promotes research-based innovation for Europe with public and societal benefit. Holm Keller, Chairman of kENUP Foundation said, “We are very grateful to the Maltese Government for the initial support in the setting up of the Foundation in the Republic of Malta. kENUP Foundation is supporting the provision of financing for companies engaged in the development of innovative products aimed at fighting COVID-19. We are therefore very happy to also contribute to the Maltese COVID-19 R&D Fund and to support projects designed to protect the Maltese people and beyond."

“With this significant donation, kENUP is giving the Malta Council for Science and Technology its appreciated support by boosting the Euro 5.3 Million COVID-19 R&D Fund set up using central government funding earlier this year,” said Dr Jeffrey Pullicino Orlando, Executive Chairman of the Malta Council for Science and Technology.

In his keynote speech, Parliamentary Secretary for Financial Services and Digital Economy Hon. Clayton Bartolo said that Malta is not a newcomer to kENUP initiatives. “I know that years ago, MCST envisioned that kENUP could truly bring something new and big to Malta’s ailing research and innovation sector. Along the years, kENUP has also found this government’s help in addressing legal issues allowing for a novel concept in online tertiary education which ultimatley led to this setting up of EDU, also in Malta.”

The Parliamentary Secretary also highlighted that six years from its inception, kENUP has solidly established itself globally in innovation support particularly in the health sector. “Through this donation our country will strengthen its cause for more investment in Research & Development,” remarked Hon. Bartolo.

The video of the event can be found at https://www.covidx.eu/news/#Malta

Contacts

Press contacts:
kENUP covidX Programme: Nadine Castillo tel: +356 99452436
MCST COVID-19 R&D fund: Giselle Calleja tel: +356 2360 2173

kENUP Foundation

Details
Headquarters: Kalkara, Republic of Malta
CEO: Holm Keller
Employees: 15
Organization: NON

Release Summary
kENUP Foundation donates €100,000 to Malta’s COVID-19 R&D Fund to further Boost Research Investment #Malta #kENUP #Research #COVID19 #MaltaGov

Contacts

Press contacts:
kENUP covidX Programme: Nadine Castillo tel: +356 99452436
MCST COVID-19 R&D fund: Giselle Calleja tel: +356 2360 2173

Social Media Profiles
More News From kENUP Foundation

Barbados’ Prime Minister Mia Amor Mottley Announces Transatlantic Bridge Between the Caribbean, Latin America and Africa to Develop and Manufacture Pharmaceuticals for Global Public Health

SHARM EL-SHEIKH, Egypt--(BUSINESS WIRE)--Today, Prime Minister of Barbados Mia Amor Mottley, President of the Co-operative Republic of Guyana H.E. Mohamed Irfaan Ali, and President of the Republic of Rwanda. H.E. Paul Kagame met in Sharm El-Sheikh on the sidelines of COP 27 to discuss the furthering of pharmaceutical equity for global public health with President of the European Commission Ursula von der Leyen, and Director-General of the World Health Organization (WHO) Dr Tedros Adhanom Ghebre...

Announcement at kENUP Roundtable: BioNTech Plans mRNA Facility in Africa in Mid-2022

KIGALI, Rwanda--(BUSINESS WIRE)--BioNTech SE today announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech’s efforts to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision is the result of a meeting between Rwanda’s Minister of Health, Dr Daniel M. Ngamije, Senegal’s Minister of Foreign Affairs Aïssata Tal...

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention

KIGALI, Rwanda--(BUSINESS WIRE)--Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy...
Back to Newsroom